Eli Lilly and Company

Nps Pharmaceuticals, Inc.

Astrazeneca Ab

Daryl Lynn Smith

Scott T Moe

Winton Dennis Jones, Jr

Thomas M Stormann

Susan M Sheehan

Leonard Larry Winneroski, Jr

Bradford C Van Wagenen

Robert M Barmore

Abdelmalik Slassi

Alan M Warshawsky

Donald Paul Matthews

Methvin Benjamin Isaac

Albert Kudzovi Amegadzie

Manuel F Balandrin

Lynn Stacy Gossett

Bradford C VanWagenen

Kevin Matthew Gardinier

Alan L Mueller

Jennifer Rebecca Allen

Linda D Artman

Jonathan Edward Green

Ruth J Walton

Donald A McLeod

George Stuart Gregory

Eric Delmar

Paul J Hoogestraat

Irina V Shcherbakova

Jennifer Ann Vance

Stephen A Hitchcock

Louise G Edwards

Tao Xin

James Robert Henry

Yanping Xu

Guoxin Zhu

Nathan Bryan Mantlo

Scott Eugene Conner

Eric G DelMar

Ian Egle

Erik James Hembre, Ii

Christopher Stanley Galka

Quanrong Shen

Daniel Ray Mayhugh

Maria Angeles Martinez-Grau

Jalaj Arora

Almudena Rubio

Xiaodong Wang

Tomislav Stefanac

Nicholas Allan Honigschmidt

Richard Trovato

Gema Ruano Plaza

Stacy Jo Keding

Steven Andrew Hitchcock

William Michne

Richard Travato

Bradford Van Wagenen

Winton Dennis Junior Jones

The present invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof, useful for treating pain, including chronic pain, chronic lower back pain, diabetic peripheral neuropathic pain, and osteoarthritis pain.

(Trifluoromethyl)pyrimidine-2-amine compounds

The present invention provides a compound of Formula I:  

(trifluoromethyl)pyrimidine-2-amine compounds

The present invention provides novel GOAT inhibitors and their salts and pharmaceutical compositions thereof.

Ghrelin 0-acyl transferase inhibitors

The present invention is directed to a compound of Formula (I): and pharmaceutically acceptable salts, solvates, hydrates or stereoisomers thereof, which are useful in treating or preventing disorders mediated by a peroxisome proliferator activated receptor (PPAR) such as syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to syndrome X and cardiovascular diseases. 

Sulfonamide derivatives as PPAR modulators

Novel compounds of structural formula (I) are disclosed. As modulators of the Cannabinoid-1 (CB1) receptor, these compounds are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. As such, compounds of the present invention are useful as in the treatment, prevention and suppression of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders (e.g., multiple sclerosis, Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis), cerebral vascular accidents, head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, particularly to opiates, alcohol, and nicotine. The compounds are also useful for the treatment of obesity or eating disorders associated with excessive food intake and complications associated therewith. 

CB1 modulator compounds

The present invention is directed to a compound of formula I, and pharmaceutically acceptable salts, solvates, hydrates or stereoisomer thereof, which are useful in treating Syndrome X, Type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to Syndrome X as well as cardiovascular diseases.

Modulators of peroxisome proliferator activated receptors (PPAR)

Novel compounds of structural formula (I) are disclosed. As modulators of the Cannabinoid-1 (CB1) receptor, these compounds are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. As such, compounds of the present invention are useful as in the treatment, prevention and suppression of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders (e.g., multiple sclerosis, Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis), cerebral vascular accidents, head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, particularly to opiates, alcohol, and nicotine. The compounds are also useful for the treatment of obesity or eating disorders associated with excessive food intake and complications associated therewith 

CB1 antagonist compounds

The present invention provides compounds and pharmaceutical compositions that act as antagonists at metabotropic glutamate receptors, and that are useful for treating neurological diseases and disorders. Methods of preparing the compounds also are disclosed.

Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists

The present invention provides compounds, and pharmaceutical compositions containing those compounds, that are active at metabotropic glutamate receptors. The compounds are useful for treating neurological diseases and disorders. Methods of preparing the compounds also are disclosed.

Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases

Bis(Fluorophenyl)alkylamides have been chemically synthesized which possess beneficial pharmacological properties (e.g., anticonvulsant activity) useful for the treatment of neurological diseases or disorders, such as, for example, epilepsy, convulsions, and seizure disorders. The preferred compounds of the invention also cause little sedation and have high therapeutic and protective indices in animal models of epilepsy. These compounds further possess long pharmacological half-lives, which, in practical clinical therapeutic application, should translate into once-a-day dosing, of great benefit to patients suffering from these diseases and/or disorders. These compounds may also be of further clinical utility in the treatment of other diseases and disorders of the central and peripheral nervous systems, or diseases or disorders affected by them, including, but not limited to, spasticity, skeletal muscle spasms and pain, restless leg syndrome, anxiety and stress, and bipolar disorder.

Anticonvulsant and central nervous system-depressing bis(fluorophenyl)alkylamides and their uses

Method and compositions for treating a patient having a neurological disease or disorder, such as stroke, head trauma, spinal cord injury, spinal cord ischemia, ischemia- or hypoxia-induced nerve cell damage, epilepsy, anxiety, neuropsychiatric or cognitive deficits due to ischemia or hypoxia such as those that frequently occur as a consequence of cardiac surgery under cardiopulmonary bypass, or neurodegenerative diseases such as Alzheimer's Disease, Huntington's Disease, Parkinson's Disease, or amyotrophic lateral sclerosis (ALS).

Compounds active at a novel site on receptor-operated calcium channels

Growing community of inventors

Fishers, IN, United States of America

Daryl Lynn Smith